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Abstract The aims of this study were to optimize the
experimental conditions for labeling extracellularly ori-
ented, solvent-exposed cysteine residues of c-aminobutyric
acid transporter 1 (GAT1) with the membrane-impermeant
sulfhydryl reagent [2-(trimethylammonium)ethyl]methane-
thiosulfonate (MTSET) and to characterize the functional
and pharmacological consequences of labeling on trans-
porter steady-state and presteady-state kinetic properties.
We expressed human GAT1 in Xenopus laevis oocytes and
used radiotracer and electrophysiological methods to assay
transporter function before and after sulfhydryl modification
with MTSET. In the presence of NaCl, transporter exposure
to MTSET (1–2.5 mM for 5–20 min) led to partial inhibi-
tion of GAT1-mediated transport, and this loss of function
was completely reversed by the reducing reagent dithio-
threitol. MTSET treatment had no functional effect on the
mutant GAT1 C74A, whereas the membrane-permeant
reagents N-ethylmaleimide and tetramethylrhodamine-6-
maleimide inhibited GABA transport mediated by GAT1
C74A. Ion replacement experiments indicated that MTSET
labeling of GAT1 could be driven to completion when
valproate replaced chloride in the labeling buffer, suggest-
ing that valproate induces a GAT1 conformation that sig-
nificantly increases C74 accessibility to the extracellular
fluid. Following partial inhibition by MTSET, there was a
proportional reduction in both the presteady-state and
steady-state macroscopic signals, and the functional and
pharmacological properties of the remaining signals
were indistinguishable from those of unlabeled GAT1.
Therefore, covalent modification of GAT1 at C74 results in
completely nonfunctional as well as electrically silent
transporters.
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Introduction
In the nervous system, removal of the inhibitory neuro-
transmitter c-aminobutyric acid (GABA) from the extra-
cellular space of neurons and glia is accomplished by
electrogenic Na?- and Cl--coupled GABA transporters
(GATs) (Borden 1996; Nelson 1998; Dalby 2003; Richerson
and Wu 2003; Conti et al. 2004). Four GAT isoforms exist in
mammalian tissues and belong to the large neurotransmitter/
Na? symporter family (NSS; 2.A.22 according to the
transporter classification system; SLC6 according to the
Human Genome Organization classification) (Nelson 1998;
Busch and Saier 2002; Chen et al. 2004; Saier et al. 2006).
Two sets of nomenclature systems are used to refer to the
GATs: rat/human GAT-1, BGT-1, GAT-2 and GAT-3 cor-
respond to mouse GAT1, GAT2, GAT3 and GAT4,
respectively. GAT1 was the first family member to be
cloned (Guastella et al. 1990; Nelson et al. 1990) and paved
the way for the cloning and characterization of the related
serotonin, dopamine, norepinephrine and glycine trans-
porters (Blakely et al. 1991; Hoffman et al. 1991; Kilty et al.
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1991; Pacholczyk et al. 1991; Shimada et al. 1991; Usdin et al.
1991; Guastella et al. 1992; Liu et al. 1992). GAT1 is the most
abundant isoform within the nervous system and is expressed
in both neurons and glia (Conti et al. 2004; Madsen et al.
2010). Tiagabine, a specific inhibitor of GAT1, is used clin-
ically as an anticonvulsant drug and highlights the importance
of GAT1 in maintaining GABA homeostasis in the brain
extracellular fluid (Dalby 2003; Schousboe et al. 2011).
Chemical modification of endogenous or engineered
cysteine residues has served as an important tool for
structure–function studies of membrane proteins (Frillingos
et al. 1998; Rudnick 2006; Guan and Kaback 2007; see also
Anderson et al. 2010); and, in particular, when coupled with
high-resolution information from crystal structures, sulf-
hydryl modification has served as a powerful tool to address
specific questions regarding the functional role of targeted
residues. Ideally, individual cysteine residues are engi-
neered in the primary protein sequence against a cysteine-
less background. Covalent modification of the introduced
cysteine with thiol-specific probes, many of which differ in
chemical properties, would then provide insight regarding
the role that the residue in question plays in protein func-
tion. In practice, however, cysteine-less membrane proteins
are difficult to study as they may not be properly trafficked
to the plasma membrane or may be nonfunctional. There-
fore, many investigators have relied on labeling endogenous
cysteines in order to glean insight about protein function.
This happens to be the case with GAT1. The extracellularly
exposed, endogenous cysteine residue of GAT1, cysteine 74
(C74), has been used to gain insight into the nature and
functional consequences of sulfhydryl modification at this
residue (Bennett and Kanner 1997; Yu et al. 1998; Gol-
ovanevsky and Kanner 1999; Li et al. 2000; Kanner 2003;
Zomot and Kanner 2003; Zhou et al. 2004, 2006; Zhou and
Kanner 2005; Zomot et al. 2005; Mari et al. 2006; Rosen-
berg and Kanner 2008; Ben-Yona and Kanner 2009; Mei-
nild et al. 2009). While it has been shown that sulfhydryl
modification at C74 renders the transporter nonfunctional,
the mechanism of this effect is not known. In previous
studies, rather harsh labeling conditions were required to
achieve any significant degree of GAT1 C74 labeling,
which made it difficult to carry out a thorough biophysical
characterization of the labeled transporter.
With the long-term goal of utilizing endogenous, extra-
cellularly oriented, solvent-exposed cysteine residues of
GAT1 for specific and targeted transporter labeling in the
Xenopus laevis oocyte plasma membrane, we set out to fully
characterize the functional consequences of sulfhydryl mod-
ification of GAT1 with the membrane-impermeant sulfhydryl
reagent [2-(trimethylammonium)ethyl]methanethiosulfonate
(MTSET). Our data suggest that C74 is very likely the only
functionally sensitive residue labeled by MTSET and that
such labeling renders the transporter nonfunctional as well as
electrically silent with respect to all known electrophysio-
logical assays of transporter function (steady-state and pre-
steady-state measurements). Labeling in the presence of
valproate, an anion that specifically interacts with GAT1 and
increases the rate of Na?/Cl-/GABA cotransport (Whitlow
et al. 2003), significantly increases the accessibility of C74 to
the extracellular fluid and, hence, allows for rapid and com-
plete labeling of all transporter copies at the cell surface. Our
findings have established the optimal conditions for labeling
GAT1 in the plasma membrane and set the stage for future
structure–function studies.
Experimental Procedures
Expression of Wild-type (WT) and Mutant GAT1
in X. laevis Oocytes
Stage V–VI X. laevis oocytes were injected with 50 ng of
complementary RNA (cRNA) for human GAT1 (SLC6A1)
(Nelson et al. 1990; Chen et al. 2004) or the mutant GAT1
C74A. The GAT1 C74A mutant was generated by poly-
merase chain reaction site-directed mutagenesis using the
QuikChange Lightning Site-Directed Mutagenesis Kit
(Agilent Technologies, La Jolla, CA). The sense (50 GG TTC
CCC TAT CTC GCC GGG AAA AAT GGT GGG 30) and
antisense (30 CC AAG GGG ATA GAG CGG CCC TTT
TTA CCA CCC 50) mutagenic primers were synthesized by
Retrogen (San Diego, CA); underlined bases denote the
mutated codon. Following site-directed mutagenesis, the
entire coding region of the plasmid containing GAT1 C74A
was sequenced (Retrogen) to confirm the proper introduction
of the mutation. cRNA for (WT) GAT1, or GAT1 C74A, was
synthesized in vitro using T7 RNA polymerase (mMessage
mMachine T7 Kit; Applied Biosystems/Ambion, Austin,
TX). After cRNA injection, oocytes were maintained in
Barth’s medium (in mM: 88 NaCl, 1 KCl, 0.33 Ca(NO3)2,
0.41 CaCl2, 0.82 MgSO4, 2.4 NaHCO3 and 10 HEPES [pH
7.4] as well as 50 lg/ml gentamicin, 100 lg/ml streptomy-
cin and 100 U/ml penicillin) at 18 C for up to 14 days until
used in experiments. Unless otherwise indicated, all exper-
iments were performed at 21 ± 2 C.
Experimental Solutions and Reagents
Unless otherwise indicated, experiments were performed in
NaCl buffer containing (in mM) 100 NaCl, 2 KCl, 1 CaCl2, 1
MgCl2 and 10 HEPES (pH 7.4). In experiments which
required Na?-free conditions, NaCl was isosmotically
replaced, depending on the experimental protocol, with cho-
line-Cl, LiCl, KCl, CsCl or tetraethylammonium-chloride.
In experiments which required Cl--free conditions, NaCl
was isosmotically replaced with Na-[2-(N-morpholino)
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ethanesulfonic acid], Na-gluconate or Na-(2-propylpentanoic
acid) (Na-valproate). In chloride-free buffers, KCl, CaCl2 and
MgCl2 were replaced with their corresponding gluconate
salts. The buffers used for solutions at pH 5.0 and 9.0 were
MES and N-tris(hydroxymethyl)methyl-3-aminopropane-
sulfonic acid, respectively. GABA, 1-(4,4-diphenyl-3-butenyl)-
3-piperidinecarboxylic acid (SKF-89976A), 1-[2-[[(diphe-
nylmethylene)imino]oxy]ethyl]-1,2,5,6-tetrahydro-3-pyridi
necarboxylic acid (NO-711), MTSET, 2-[(methylsulfonyl)
thio]ethanesulfonic acid (MTSES, sodium salt),
N-ethylmaleimide (NEM), tetramethylrhodamine-6-mal-
eimide (TMR6M) and/or dithiothreitol (DTT) was added to
the experimental solution as indicated. Stock solutions of
sulfhydryl reagents (MTSET, MTSES, NEM and TMR6M)
were stored in nanopure water (MTSET, MTSES), absolute
ethanol (NEM) or dimethyl sulfoxide (TMR6M) at -20 C
and diluted in the experimental solution immediately before
use. DTT was prepared from the solid material immediately
before use. MTSET and MTSES were purchased from
Toronto Research Chemicals (Toronto, ON, Canada) or
Anatrace (Maumee, OH). TMR6M was purchased from
Invitrogen (Carlsbad, CA). [3H]-GABA was obtained from
GE Healthcare (Piscataway, NJ). All other reagents were
purchased from Fisher Scientific (Pittsburgh, PA) or Sigma
(St. Louis, MO).
Electrophysiological Measurements and Data Analysis
The two-microelectrode voltage-clamp technique was used
for the recording of whole-cell transporter-mediated cur-
rents. Oocytes were voltage-clamped at the indicated
membrane potential (Vm) using the Warner oocyte clamp
(OC-725C; Warner Instrument; Hamden, CT). In the
experimental recording chamber, oocytes were initially
stabilized in NaCl buffer, and the composition of the bath
was changed as indicated. In all experiments, reference
electrodes were connected to the experimental oocyte
chamber via agar bridges (3 % agar in 3 M KCl). For
continuous holding current measurements, currents were
low pass-filtered at 1 Hz (LPF 8, Warner Instrument) and
sampled at 10 Hz (pCLAMP 8.1; Axon Instruments, Union
City, CA). The GABA-evoked current was obtained as the
difference in steady-state current in the absence and pres-
ence of GABA and/or inhibitor. As the GAT1-mediated,
GABA-evoked current is Na?- and Cl--coupled (Loo et al.
2000), it is referred to as IGABANaCl (Gonzales et al. 2007).
The effects of substrate concentration ([GABA]o, [Na
?]o
and [Cl-]o) on the steady-state kinetics were determined by





 nþ S½ n ð1Þ
where S is the substrate (GABA, Na? or Cl-), ISmax is the
maximal substrate-induced current, KS0:5 is the substrate
concentration at half ISmax (half-maximal concentration) and
n is the Hill coefficient. For kinetic characterization of Cl-
activation of the inward currents, an additional linear term
was added to Eq. 1 in order to account for the nonzero
baseline at zero Cl- concentration (see Fig. 6g–i).
To examine the carrier-mediated presteady-state current
transients, the pulse protocol consisted of voltage jumps
(400 ms) from the holding voltage (-50 mV) to test
voltages ranging from ?80 to -130 mV in 15-mV steps.
Unless otherwise indicated, voltage pulses were separated
by an interval of at least 3 s in order to allow for complete
relaxation of the OFF transients (see Sacher et al. 2002;
Karakossian et al. 2005). Currents were low pass-filtered at
1 kHz and sampled at 12.5 kHz without averaging. To
obtain the transporter presteady-state currents, at each Vm,
the total current for the ON transients, I(t), was fitted with
Eq. 2:
I tð Þ ¼ I1et=s1 þ I2et=s2 þ ISS ð2Þ
where t is time, I1e
t=s1 is the oocyte capacitive transient
current with initial value I1 and time constant s1, I2et=s2 is
the transporter transient current with initial value I2 and
time constant s2 and Iss is the steady-state current (Loo
et al. 1993; Hazama et al. 1997). At each Vm, the total
transporter-mediated charge (Q) was obtained by
integration of the transporter transient currents. The
charge–voltage (Q–V) relations obtained were then fitted








where QNaCl = Qdep - Qhyp (Qdep and Qhyp are Q at
depolarizing and hyperpolarizing limits, respectively) and
represents the maximum charge moved (i.e., Qmax), z is the
apparent valence of movable charge, d is the fraction of the
membrane electric field traversed by the charge, V0.5 is the
Vm for 50 % charge movement, F is Faraday’s constant, R
is the gas constant and T is the absolute temperature.
The inhibition experiments involved GAT1-specific com-
petitive inhibitors of GABA transport (SKF-89976A and NO-
711). Data for the inhibition experiments were fitted with








where Imax is the maximum current evoked by a saturating
concentration of GABA in the absence of the blocker (B,
here SKF-89976A or NO-711), I is the evoked current in
the presence of the indicated concentrations of GABA and
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blocker (B), KGABA0:5 is the GABA concentration at which I
is half of Imax (25 lM at -50 mV) (Gonzales et al. 2007)
and KBi is the blocker concentration at which I is 50 % of
Imax (apparent half-inhibition constant).
To determine the effect of sulfhydryl modification on the
ratio of GAT1-mediated charge flux to GABA flux across the
plasma membrane, uptake experiments were performed under
voltage clamp in individual control oocytes and oocytes
expressing WT GAT1 (Eskandari et al. 1997; Forster et al.
1999; Loo et al. 2000; Sacher et al. 2002; Whitlow et al. 2003;
Karakossian et al. 2005; Gonzales et al. 2007; Matthews et al.
2009). The membrane potential was held at the indicated value
(-50 mV), and the holding current was continuously moni-
tored. Oocytes were initially incubated in NaCl buffer until a
baseline was established. GABA (500 lM) and [3H]-GABA
(20 nM) were added to the perfusion solution for 5–10 min.
At the end of the incubation period, GABA and the isotope
were removed from the perfusion solution until the holding
current returned to baseline. Oocytes were removed from the
experimental chamber, washed in ice-cold choline-Cl buffer
and solubilized in 10 % sodium dodecyl sulfate (SDS). Oocyte
[3H]-GABA content was determined in a liquid scintillation
counter (LS 6500; Beckman, Fullerton, CA). Net inward
charge was obtained from the time integral of the GABA-
evoked inward current and correlated with GABA influx in the
same cell. GABA uptake under voltage clamp was also per-
formed in oocytes expressing WT GAT1 after a 5-min
exposure to 1 mM MTSET in NaCl buffer. This treatment
reduces the GAT1-mediated, GABA-evoked current by
approximately 50 % (see Figs. 1, 2, 3, 4, 7). In all experi-
ments, the GAT1-mediated GABA uptake was obtained by
subtracting endogenous GABA uptake in control cells from
the same batch that were subjected to the same experimental
condition as GAT1-expressing cells. Depending on the level
of GAT1 expression in the plasma membrane as well as the
duration of GABA exposure (5–10 min), the magnitude of
endogenous GABA uptake was 0.5–5 % of the total GABA
uptake (endogenous plus GAT1-mediated uptake).
Where sample sizes are indicated (n), they refer to the
number of oocytes in which the experiments were repeated.
Reported errors represent the standard error of the mean
obtained from data from several oocytes.
Results
Labeling with the Membrane-Impermeant Sulfhydryl
Reagent MTSET Leads to Functional Modification
of WT GAT1 but not the Mutant GAT1 C74A
Figure 1 shows the basic experimental approach used
to assess the effect of sulfhydryl modification on the
GABA-evoked current mediated by GAT1 (IGABANaCl ). I
GABA
NaCl
is proportional to the number of functional transporters in
the plasma membrane and is directly related to Na?/Cl-/
GABA cotransport across the plasma membrane (Loo et al.
2000; Gonzales et al. 2007; Matthews et al. 2009). It is,
therefore, a good assay of GAT function. In a typical
experiment, IGABANaCl was measured in NaCl buffer (plus
500 lM GABA) before and after exposure to MTSET. In
the experiments of Fig. 1, MTSET labeling was carried out
in NaCl buffer at 1 mM for 5 min (at 21 ± 2 C, Vm =
-50 mV, pH 7.4). The evoked current obtained after
MTSET exposure was normalized to that before MTSET
and was 52 ± 1 % of the original value (n = 4) (Fig. 1a,
d). Treatment with the membrane-impermeant MTSES (at
1 mM for 5 min at 21 ± 2 C, Vm = -50 mV, pH 7.4)
reduced IGABANaCl by only 22 ± 2 % (n = 3, data not shown).
Therefore, we focused on the effect of MTSET for the
remaining experiments of this study. In all subsequent
experiments, where normalized current values are reported,
they always refer to measurements obtained in NaCl buffer
(500 lM GABA at 21 ± 2 C, Vm = -50 mV, pH 7.4).
However, the labeling conditions were altered depending
on the experimental objective. Unless otherwise stated, the
labeling conditions consisted of 1 mM MTSET for 5 min
in NaCl buffer at 21 ± 2 C, Vm = -50 mV, pH 7.4.
Similar to WT GAT1, GAT1 C74A mediates Na?-
dependent and Cl--facilitated GABA transport (see
Fig. 6). Exposure of GAT1 C74A to MTSET (1 mM for
5 min) had no effect on the magnitude of the GABA-
evoked current (Fig. 1b, d). This result suggests that C74 is
very likely the only functionally significant cysteine resi-
due that is exposed to the extracellular fluid (and hence
accessible to the membrane-impermeant MTSET).
The reduction in WT GAT1 IGABANaCl caused by MTSET
sulfhydryl modification was completely reversible with
DTT. Following DTT treatment (12 mM for 10 min),
IGABANaCl returned to 98 ± 3 % of its original level before
MTSET labeling (n = 5) (Fig. 1c, d). Treatment of WT
GAT1 with DTT, either before or during exposure to
GABA, was without any effect on the GABA-evoked
current. In the copresence of 500 lM GABA and 10 mM
DTT, IGABANaCl was 98 ± 2 % of that measured in the same
cell in the absence of DTT (n = 3) (not shown).
The above results suggest that any functional conse-
quence of sulfhydryl modification of WT GAT1 by
MTSET very likely occurred at position C74. NEM, a
membrane-permeant thiol modification reagent, led to a
significant reduction in IGABANaCl mediated by both WT GAT1
(21 ± 5 %, n = 4) and GAT1 C74A (51 ± 6 %, n = 5)
(Fig. 1d). These results further suggest that C74 is very
likely the only functionally sensitive cysteine residue
exposed to the extracellular fluid. TMR6M, a fluorescent
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probe commonly used for labeling membrane proteins at
solvent-exposed cysteine residues, reduced IGABANaCl mediated
by WT GAT1 to 53 ± 4 % (n = 3) and that mediated by
GAT1 C74A to 75 ± 3 % (n = 6) of control levels
(Fig. 1d).
As the long-term objective of this project is to utilize
extracellularly exposed cysteine residues to label and
quantify the number of transporter copies in the plasma
membrane, we carried out a complete characterization of
labeling WT GAT1 with MTSET with the goal of identi-
fying experimental conditions that drive the labeling
reaction to completion (i.e., 100 % labeling of transporter
copies in the plasma membrane). Understanding these
conditions would then allow us to pursue future labeling
and quantification studies.
The Inhibitory Effect of MTSET is Dependent
on the Composition of the Labeling Buffer
GABA transport by the GATs is Na?- and Cl--coupled,
and indeed, Na? and Cl- interaction with the transporter
leads to conformational changes (Golovanevsky and Kan-
ner 1999; Lu and Hilgemann 1999b; Li et al. 2000; Zomot
and Kanner 2003; Meinild et al. 2009). Therefore, we
explored the possibility that the ionic composition of the
buffer in which the MTSET exposure takes place can
potentially enhance the solvent accessibility of C74, thus
increasing the degree of labeling. To accomplish this, we
investigated the degree of MTSET labeling when Na?
and/or Cl- was isosmotically replaced with various cat-
ions/anions in the labeling buffer, keeping all other label-
ing conditions constant (1 mM MTSET for 5 min at 21 ±
2 C, Vm = –50 mV, pH 7.4).
Labeling with MTSET in the standard NaCl conditions
reduced IGABANaCl to 52 ± 1 % of control levels (Figs. 1, 2).
When Na? in the labeling buffer was replaced with other
cations such as choline, TEA, Cs?, K? or Li?, there was
only a marginal enhancement of the inhibitory effect of
MTSET (Fig. 2). The largest effect of Na? replacement
was seen with Li? (Fig. 2). Similarly, replacing Cl- in the
labeling buffer with anions such as MES or gluconate only
modestly enhanced the inhibitory effect of MTSET. Nei-
ther replacement of both Na? and Cl- in the labeling buffer
(with TEA and MES, respectively) nor increasing the NaCl
concentration to 150 mM led to any significant increase in
the degree of MTSET labeling (Fig. 2). Notably, labeling
with MTSET when Cl- was replaced with valproate
resulted in significantly enhanced efficacy of the MTSET-
dependent reduction in IGABANaCl (13 ± 2 % of control,
n = 4). On the other hand, the presence of GABA during
MTSET treatment protected against transporter labeling
(Fig. 2). Addition of 0.5 and 5 mM GABA to the labeling
Fig. 1 WT GAT1, but not GAT1 C74A, is sensitive to membrane-
impermeant sulfhydryl reagents. a A representative GABA-evoked
(500 lM) current trace is shown for WT GAT1 before and after
labeling with the membrane-impermeant sulfhydryl reagent MTSET.
Labeling of GAT1 with MTSET led to *50 % reduction in the
GABA-evoked current. The membrane potential (Vm) was -50 mV
throughout the experiment. Labeling was carried out at 1 mM MTSET
for 5 min in NaCl buffer bathing the oocyte (at 21 ± 2 C, pH 7.4).
b Similar to WT GAT1, GAT1 C74A mediates Na?-dependent and
Cl--facilitated GABA transport (see Fig. 6). Exposure of GAT1 C74A
to MTSET (1 mM for 5 min) had no effect on the magnitude of the
GABA-evoked (500 lM) current. c Sulfhydryl modification of WT
GAT1 with MTSET was completely reversed with DTT. Labeling with
MTSET was carried out as in (a), and DTT was applied at 12 mM for
10 min in NaCl buffer. d Summary of data collected from four or more
oocytes expressing WT GAT1 or GAT1 C74A. For each experimental
condition, the GABA-evoked current obtained after labeling with
MTSET, NEM or TMR6M (all at 1 mM for 5 min at -50 mV) was
normalized to that prior to sulfhydryl modification in the same cell.
Reported values represent the mean ± SE from four or more oocytes.
Note that GAT1 C74A is insensitive to the membrane-impermeant
MTSET but sensitive to the membrane-permeant NEM. GAT1 C74A
was also sensitive to TMR6M
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buffer reduced IGABANaCl to only 70 ± 3 % (n = 3) and 82 ±
2 % (n = 3) of control levels prior to MTSET labeling
(Fig. 2).
Changes in Membrane Potential, pH and Temperature
Do Not Alter the Effect of MTSET
GAT activity is also known to be altered by changes in
membrane potential (Mager et al. 1993, 1996; Lu and Hil-
gemann 1999a, b; Gonzales et al. 2007), pH (Grossman and
Nelson 2002, 2003) and temperature (Lu and Hilgemann
1999a; Binda et al. 2002; Gonzales et al. 2007; Matthews
et al. 2009). Therefore, we examined the influence of these
factors on the degree of MTSET labeling of GAT1. In the
experiments of Fig. 3, membrane potential (Vm), pH and
temperature were independently perturbed during the
MTSET labeling period, while all other parameters were
held constant according to our standard labeling conditions:
1 mM MTSET for 5 min at 21 ± 2 C, Vm = -50 mV and
pH 7.4. Interestingly, changes in the membrane potential or
pH of the labeling buffer or in temperature had little to no
effect on the efficacy of MTSET labeling (Fig. 3). The
apparent reduction in MTSET labeling at lower pH values
(Fig. 3b) is unlikely to be a direct conformational effect on
the transporter (see ‘‘Discussion’’ Section).
MTSET Labeling Conditions for Complete Elimination
of GAT1-Mediated GABA Transport
In further pursuit of the optimal experimental conditions
under which MTSET labeling of WT GAT1 would
approach completion, we examined the effect of MTSET
concentration (Fig. 4a) and labeling duration (Fig. 4c) on
GAT1-mediated, GABA-evoked current. The concentra-
tion dependence of MTSET labeling in NaCl buffer is
shown in Fig. 4a. Keeping all other labeling conditions
constant, increasing the concentration of MTSET from 1 to
Fig. 2 Effect of buffer composition on MTSET labeling of WT
GAT1. WT GAT1 was labeled with MTSET in the indicated
extracellular bathing solution, in which Na? and/or Cl- of the NaCl
buffer had been isosmotically replaced by another cation or anion,
respectively. The experimental protocol was similar to that shown in
Fig. 1 (5-min exposure to 1 mM MTSET at -50 mV, 21 ± 2 C, pH
7.4) with the exception that sulfhydryl modification was carried out in
the indicated buffer. The GABA-evoked (500 lM in NaCl buffer)
current after MTSET modification was normalized to that obtained in
the same cell before exposure to MTSET. Reported values represent
the mean ± SE from three or more oocytes
Fig. 3 Effect of membrane potential, pH and temperature on MTSET
labeling of WT GAT1. The GABA-evoked (500 lM at -50 mV)
current mediated by WT GAT1 was measured before and after
MTSET labeling (1 mM for 5 min) at different membrane potential
values (a), extracellular pH values (b) and experimental temperatures
(c). In all experiments, labeling was carried out in NaCl buffer.
Labeling was performed at the indicated membrane potential values
for the experiments of a and at -50 mV for the experiments of
(b) and (c). Labeling was performed at pH 7.4 for the experiments of
(a) and (c) and at the indicated values for the experiments of (b).
Labeling was performed at 21 C for the experiments of (a) and
(b) and at the indicated values for the experiments of (c). The GABA-
evoked current after MTSET modification was normalized to that
obtained in the same cell before exposure to MTSET. Reported values
represent the mean ± SE from three or more oocytes
846 J. J. Omoto et al.: Sulfhydryl Modification of GAT1 at Cysteine 74
123
2.5 mM slightly decreased the normalized IGABANaCl current
from 52 ± 1 % (n = 4) to 48 ± 1 % (n = 4) of values
prior to MTSET labeling. The estimated Ki for MTSET
inhibition of IGABANaCl was 1.6 ± 0.2 mM. Inclusion of val-
proate in the labeling buffer significantly enhanced the
labeling efficacy of MTSET (see Fig. 2). The half-maximal
concentration for the valproate-induced enhancement of
MTSET labeling was estimated to be 16 ± 3 mM (n = 3)
(Fig. 4b).
Increasing the MTSET incubation time in NaCl buffer to
20 min decreased the GAT1-mediated, GABA-evoked cur-
rent to 34 ± 1 % at 1 mM MTSET (n = 3) and 12 ± 1 % at
2.5 mM MTSET (n = 3) (Fig. 4c). Similarly, MTSET
incubation in LiCl buffer for up to 20 min failed to lead to
100 % elimination of IGABANaCl (Fig. 4c). However, labeling
with 2.5 mM MTSET in the presence of Na-valproate
for C10 min brought about complete elimination of
GAT1-mediated GABA transport (Fig. 4c). The second-order
rate constants (Zhang and Karlin 1997) for MTSET labeling of
WT GAT1 were determined to be 0.79 ± 0.21 M-1 s-1
(1 mM MTSET in NaCl), 2.0 ± 0.2 M-1 s-1 (2.5 mM
MTSET in NaCl), 1.2 ± 0.3 M-1 s-1 (1 mM MTSET in
LiCl), 3.7 ± 0.4 M-1 s-1 (1 mM MTSET in Na-valproate)
and 6.4 ± 0.5 M-1 s-1 (2.5 mM MTSET in Na-valproate).
Importantly, IGABANaCl mediated by GAT1 C74A was not
inhibited by MTSET under any labeling condition
(Fig. 4c). Taken together, these results further support the
notion that C74 is only partially exposed to the extracel-
lular fluid and that ionic interactions with the transporter
can enhance the solvent accessibility of this residue
(Yu et al. 1998; Meinild et al. 2009).
Thus far, the results demonstrate that sulfhydryl modifi-
cation of GAT1 at C74 leads to a reduction in the GABA-
evoked current (IGABANaCl ). In order to better understand the
Fig. 4 Effect of MTSET concentration and labeling duration on
sulfhydryl modification of WT GAT1. a Sulfhydryl modification of WT
GAT1 was carried out for 5 min in NaCl buffer in the presence of the
indicated concentration of MTSET. b Sulfhydryl modification of WT
GAT1 was carried out at 1 mM MTSET for 5 min in the presence of the
indicated concentration of valproate. [Na?] = 100 mM. c Duration of
labeling with 1 or 2.5 mM MTSET was varied (up to 20 min) in NaCl,
LiCl or Na-valproate buffer for WT GAT1 or GAT1 C74A. Note that
under all conditions GAT1 C74A was functionally insensitive to
MTSET exposure. See text for the second-order rate constants for
MTSET labeling of WT GAT1 under different conditions. In all
experiments, labeling was carried out at -50 mV. In all experiments,
the GABA-evoked (500 lM in NaCl buffer at -50 mV) current after
MTSET modification was normalized to that obtained in the same cell
before exposure to MTSET. Reported values represent the mean ± SE
from three or more oocytes
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mechanism by which MTSET labeling of WT GAT1 leads to
a reduction in IGABANaCl , we carried out a comprehensive char-
acterization of the current that remains after partial labeling
with 1 mM MTSET for 5 min (see Fig. 1). In principle, the
reduction in IGABANaCl may be due to (1) a change in the trans-
porter ion/GABA flux coupling ratio; (2) a significant
increase in the apparent affinity constant (K0.5) values (i.e.,
reduction in the apparent affinity) for the transporter
cosubstrates Na?, Cl- and GABA; (3) a reduction in trans-
porter turnover rate (i.e., the rate at which ion/GABA
molecules are cotranslocated across the plasma membrane
per unit time); or (4) a complete loss of GAT1 GABA
transport activity when C74 is chemically modified by
MTSET. The experiments of Figs. 5, 6, 7, 8 and 9 examine
these four possibilities. In all of the following experiments,
WT GAT1 was labeled with 1 mM MTSET for 5 min (at
21 ± 2 C, Vm = -50 mV and pH 7.4) in order to achieve
*50 % reduction in IGABANaCl (see Figs. 1, 2, 3, 4). This
‘‘partial labeling’’ protocol allowed us to carry out a com-
plete functional characterization of IGABANaCl after MTSET
labeling.
Sulfhydryl Modification of GAT1 C74 Does Not Alter
GAT1-Mediated Charge/GABA Flux Ratio
Translocation of GABA by GAT1 across the plasma
membrane is coupled to cotranslocation of Na? and Cl-
(Radian and Kanner 1983; Keynan and Kanner 1988; Loo
et al. 2000), and recent studies suggest that Na?/Cl-/
GABA cotransport is a tightly coupled process (Gonzales
et al. 2007; Matthews et al. 2009). To examine the possi-
bility that MTSET modification of C74 leads to a change in
the ion/GABA coupling ratio of GAT1, we performed
GABA uptake under voltage-clamp experiments (Fig. 5).
In these experiments, [3H]-GABA uptake was measured
under voltage clamp in individual GAT1-expressing cells
in the absence of MTSET labeling (Fig. 5a, c) or after
labeling with 1 mM MTSET for 5 min (at 21 ± 2 C,
Vm = –50 mV and pH 7.4) (Fig. 5b, c). This experimental
protocol yielded two measured parameters for each cell: (1)
net GABA-evoked inward charge translocation during the
recording period (charge flux) and (2) GABA uptake in the
same cell (GABA flux) (Fig. 5c). The ratio of charge flux
Fig. 5 Sulfhydryl modification of WT GAT1 with MTSET does not
alter the ion/GABA transport coupling ratio. GABA-uptake experi-
ments were performed under voltage clamp without MTSET treat-
ment (a) or after labeling with 1 mM MTSET for 5 min (b). Vm =
-50 mV. c Cells expressing GAT1 were exposed to 500 lM GABA
and 20 nM [3H]-GABA for 5–10 min. After washout of GABA and
isotope, cells were solubilized in 10 % SDS and intracellular GABA
content was determined using a liquid scintillation counter. In the
same cell, the net inward charge flux was obtained from the time
integral of the GABA-evoked current trace. The ratio of charge flux
to GABA flux (i.e., net positive charges per GABA, e/GABA) was
2.1 ± 0.1 whether or not the cell was exposed to MTSET (n = 8
and 8). The smooth line in (c) is a linear regression through all data
points
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to GABA flux was 2.1 ± 0.1 whether or not the cell was
exposed to MTSET (Fig. 5c).
Sulfhydryl Modification of GAT1 C74 Does Not Alter
Transporter Steady-State or Presteady-State Kinetic
Parameters
To determine if MTSET modification of GAT1 C74 alters
the transporter steady-state kinetic properties, we per-
formed steady-state kinetic experiments for GABA, Na?
and Cl- in WT GAT1 before and after labeling with
MTSET (1 mM for 5 min in NaCl buffer) (Fig. 6). The
results of these experiments show that the apparent affinity
constants for GABA (26 ± 3 vs. 22 ± 4 lM, Fig. 6a, b),
Na? (66 ± 10 vs. 72 ± 7 mM, Fig. 6d, e) and Cl-
(42 ± 6 vs. 38 ± 5 mM, Fig. 6g, h) were not significantly
different before and after partial labeling with 1 mM
MTSET for 5 min. Moreover, the Hill coefficient for Na?
activation of the currents was the same before and after
sulfhydryl modification of C74 (Fig. 6d, e). The apparent
affinity constants of the mutant GAT1 C74A for GABA
(22 ± 4 lM, Fig. 6c), Na? (75 ± 10 mM, Fig. 6f) and
Fig. 6 Steady-state kinetic parameters of WT GAT1 before and after
sulfhydryl modification with MTSET. Representative GABA (a–c),
Na? (d–f) and Cl- (g–i) steady-state kinetic curves are shown for WT
GAT1 before (left panels) and after (middle panels) treatment with
MTSET (1 mM for 5 min at -50 mV) as well as for GAT1 C74A
without MTSET treatment (right panels). The half-maximal concen-
tration values (K0.5) for GABA, Na
? and Cl- were similar for WT
GAT1 and GAT1 C74A. The Hill coefficient values for Na? and Cl-
activation of the inward currents were also similar for WT GAT1 and
GAT1 C74A. Moreover, MTSET exposure had no effect on WT
GAT1 steady-state kinetic parameters. Vm = -50 mV. For GABA
kinetic experiments (a–c), [Na?]0 was 100 mM and [Cl
-] was
106 mM. For sodium kinetic experiments (d–f), [Cl-] was 106 mM
and [GABA]0 was 5 mM. For chloride kinetic experiments (g–i),
[Na?]0 was 100 mM and [GABA]0 was 5 mM. The smooth lines
represent fits of the experimental data with Eq. 1 (see ‘‘Experimental
Procedures’’ Section). Reported values represent the mean ± SE from
three or more oocytes
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Cl- (40 ± 4 mM, Fig. 6i) were not significantly different
from those of WT GAT1.
To further characterize the behavior of WT GAT1 after
partial labeling with 1 mM MTSET for 5 min, we inves-
tigated the sensitivity of WT GAT1 to known transporter
inhibitors before and after sulfhydryl modification (Fig. 7).
The apparent half-inhibition constant values for SKF-
89976A (940 ± 50 vs. 910 ± 50 nM, Fig. 7b, c) and
NO-711 (24 ± 6 vs. 31 ± 5 nM, Fig. 7e, f) were not sig-
nificantly different before and after sulfhydryl labeling
with MTSET. Moreover, the apparent half-inhibition con-
stant values of GAT1 C74A for SKF-89976A (910 ± 150 nM,
Fig. 7d) and NO-711 (28 ± 5 nM, Fig. 7g) were similar to
those of WT GAT1.
To examine the effect of MTSET labeling on WT GAT1
voltage-evoked presteady-state currents, 400-ms voltage
pulses were applied, from a holding voltage of -50 mV to
test voltages ranging from ?80 to -130 mV in 15-mV
steps, before (Fig. 8a) and after (Fig. 8b) labeling with
1 mM MTSET for 5 min. At each voltage, the evoked
current transient was analyzed to obtain the GAT1-medi-
ated charge moved (see ‘‘Experimental Procedures’’ Sec-
tion), and the resulting presteady-state charge was plotted
as a function of the test voltage to obtain the Q–V rela-
tionships (Fig. 8d, e). After labeling WT GAT1 with 1 mM
MTSET for 5 min, QNaCl was reduced to 60 ± 8 %
(n = 4) of that prior to MTSET treatment (compare
Fig. 8d, e), suggesting a similar degree of loss of function
Fig. 7 Sulfhydryl modification with MTSET has no effect on WT
GAT1 sensitivity to transport inhibitors. a A representative WT
GAT1 current trace is shown for inhibition of the GABA-evoked
(500 lM at -50 mV) current with SKF-89976A (a specific inhibitor
of GAT1) following sulfhydryl modification with MTSET (1 mM for
5 min at -50 mV). Similar to that shown in this panel, inhibition
kinetics experiments were performed with SKF-89976A or NO-711
for WT GAT1 without (b, e) or with (c, f) prior exposure to MTSET
(1 mM for 5 min at -50 mV) as well as for GAT1 C74A without
MTSET treatment (d, g). Sulfhydryl modification of WT GAT1 had
no effect on the Ki values for SKF-89976A or NO-711. Moreover, the
Ki values for SKF-89976A (d) and NO-711 (g) inhibition of GAT1
C74A GABA-evoked currents were not different from those of WT
GAT1. The smooth lines in (b–g) represent fits of the experimental
data with an equation for competitive inhibition at a single binding
site (Eq. 4, see ‘‘Experimental Procedures’’ section). Reported Ki
values represent the mean ± SE from three or more oocytes
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as that seen with steady-state GABA-evoked current
(IGABANaCl ) (see Figs. 1, 2, 3). Neither the midpoint of the Q–V
relationship (V0.5, 25 ± 5 vs. 22 ± 6 mV) nor the apparent
valence of the moveable charge (zd, 0.9 ± 0.1 vs.
0.9 ± 0.1) was different after MTSET treatment (Fig. 8d,
e). Furthermore, the ON and OFF relaxation time constants
were not altered after MTSET treatment (Fig. 8g, h).
Finally, the presteady-state kinetic properties of GAT1
C74A were similar to those of WT GAT1 (Fig. 8c, f, i).
Sulfhydryl Modification of GAT1 C74 Does Not Alter
Transporter Turnover Rate
Turnover rate is the rate at which ion/GABA molecules are
cotranslocated across the plasma membrane per unit time. In
a comprehensive characterization, the GAT1 turnover rate
was determined to be 15 GABA molecules per second at
21 C, -50 mV and physiological ion concentrations
(Gonzales et al. 2007). When extrapolated to the
Fig. 8 Presteady-state charge movements of WT GAT1 before and
after sulfhydryl modification with MTSET. a–c Representative cur-
rent relaxations are shown in response to 400-ms voltage pulses from
?80 to -130 mV for WT GAT1 before (a) and after (b) treatment
with MTSET (1 mM for 5 min) as well as for GAT1 C74A without
MTSET treatment (c). Holding potential was -50 mV. d–f For each
evoked current trace, time integration of the ON presteady-state
currents yielded the total charge moved (QON) and, when plotted as a
function of the test voltage, the Q–V relationship for WT GAT1
before (d) and after (e) labeling with MTSET as well as for GAT1
C74A (f). The smooth lines in (d–f) represent the fit of the data with a
Boltzmann function (Eq. 3, see ‘‘Experimental Procedures’’ section).
g–i Presteady-state currents monoexponentially decay to the zero
level. The time constant plotted as a function of the test voltage
yielded the s–V relationship. The smooth lines in (g–i) represent the fit
of the data with a gaussian function (Sacher et al. 2002). While
MTSET treatment led to a reduction in the total charge moved
(compare d and e), it had no effect on the midpoint of the
Q–V relationship (V0.5) and no effect on the relaxation time constants
(compare g and h). The presteady-state parameters of GAT1 C74A
were not different from those of WT GAT1. See text for additional
details
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physiological temperature of 37 C, the turnover rate was
estimated to be 79 s-1 (Gonzales et al. 2007). An important
prerequisite to characterizing the turnover rate is the ratio of
the maximum GABA-evoked current (IGABANaCl ) to the maxi-
mum presteady-state charge movements (QNaCl). Both
IGABANaCl and QNaCl are directly proportional to the total number
of functional transporters in the cell plasma membrane
(Gonzales et al. 2007). The ratio of IGABANaCl to QNaCl is directly
proportional to the turnover rate and, therefore, can be used
as an index of the transporter turnover rate (for details, see
Gonzales et al. 2007). At any given membrane potential, the
maximum GABA-evoked current (IGABANaCl ) is measured at
steady state after application of GABA at a saturating con-
centration (C5 mM). The maximum presteady-state charge
movement (QNaCl) is determined in the absence of GABA
from analyzing presteady-state current transients evoked in
response to step changes in the membrane potential (Sacher
et al. 2002; Whitlow et al. 2003; Karakossian et al. 2005;
Gonzales et al. 2007). The results of typical presteady-state
charge movement experiments are shown in Fig. 8, and the
ratio of IGABANaCl to QNaCl is shown in Fig. 9.
The ratio of IGABANaCl to QNaCl (i.e., index of turnover rate)
for WT GAT1 was the same before and after sulfhydryl
modification with 1 mM MTSET for 5 min (4.1 ± 0.2 vs.
4.0 ± 0.2 s-1, n = 4 and 4). Moreover, this ratio was
similar for GAT1 C74A (4.1 ± 0.2 s-1, n = 7).
Discussion
In anticipation of utilizing extracellularly oriented, solvent-
exposed cysteine residues of GAT1 for labeling and
quantifying the transporter in the plasma membrane, the
primary objective of this study was to characterize the
functional consequences of sulfhydryl modification of
GAT1 with the membrane-impermeant sulfhydryl reagent
MTSET. Our results show that exposure of the extracel-
lular surface of WT GAT1 to MTSET resulted in a sig-
nificant and proportional, yet reversible, decrease in both
the steady-state GABA-evoked current as well as the pre-
steady-state charge movements. Labeling proved to be
insensitive to changes in membrane potential, temperature
and pH. Labeling was relatively insensitive to changes in
Na? and/or Cl- concentration when Na? was replaced with
cations such as choline or tetraethylammonium or when
Cl- was replaced with anions such as gluconate or MES.
However, substitution of Cl- with valproate significantly
increased the rate of labeling with MTSET, driving it to
completion and leading to a complete loss of transporter
function.
GAT1 contains 14 cysteine residues, of which only three
(C74, C164, C173) are predicted to be exposed to the
extracellular fluid. C74 is in the first transmembrane
domain near the membrane/extracellular fluid interface.
C164 and C173 are located in the extracellular loop con-
necting transmembrane domains 3 and 4, and there is
evidence that these as well as homologous residues of the
related serotonin and dopamine transporters form a disul-
fide bridge under most conditions (Chen et al. 1997, 2007).
Site-directed mutagenesis revealed that the site of covalent
sulfhydryl modification of GAT1 is most likely the cys-
teine at position 74. Our data cannot rule out the possibility
that the functional consequence of labeling is due to
modification of a cysteine residue other than C74, whose
accessibility is altered in the mutant C74A. However,
considering the totality of our data set (insensitivity of
C74A to MTSET and virtually identical steady-state state
and presteady-state kinetic properties of WT and GAT1
C74A), it is plausible to conclude that C74 is very likely
the only functionally sensitive cysteine residue that is
labeled by MTSET. Extensive functional characterization
suggested that GAT1 C74 is only partially accessible from
the extracellular fluid. However, once covalently modified
with MTSET, GAT1 is incapable of undergoing the con-
formational changes necessary for presteady-state tran-
sients or Na?/Cl-/GABA cotranslocation across the
plasma membrane.
Our first goal was to optimize the experimental condi-
tions under which all GAT1 copies in the plasma mem-
brane could be rapidly labeled with MTSET, while
maintaining cellular and plasma membrane integrity such
that accurate biophysical measurements could be carried
out. Initial time and concentration dependence of MTSET
labeling of GAT1 demonstrated that, under most labeling
conditions, very long incubation times at high MTSET
Fig. 9 Sulfhydryl modification with MTSET has no effect on WT
GAT1 turnover rate. The ratio of IGABANaCl to QNaCl is used as an index of
the transporter turnover rate (Gonzales et al. 2007). IGABANaCl represents
the maximum GABA-evoked current and was measured at 5 mM
GABA and -50 mV (in NaCl buffer). QNaCl represents the total
charge moved in response to ON voltage pulses and was measured in
NaCl buffer according to the procedures described for the experi-
ments of Fig. 8. Sulfhydryl modification with MTSET had no effect
on the ratio of IGABANaCl to QNaCl (4.1 ± 0.2 vs. 4.0 ± 0.2 s
-1, n = 4 and
4). The ratio was also similar in GAT1 C74A (4.1 ± 0.2 s-1, n = 7)
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concentrations are required to approach complete labeling
of all transporter copies in the plasma membrane. This
observation is not consistent with the very high intrinsic
reactivity of methanethiosulfonate reagents toward free
thiol groups (Karlin and Akabas 1998) and suggests that
C74 is only partially exposed to the extracellular fluid, such
that accessibility of this site to MTSET is restricted (Yu
et al. 1998). Indeed, sequence alignments of GAT1 with the
related bacterial leucine transporter (LeuTAa) and other
members of the SLC6A family of transporters, as well as
homology models of GAT1 built using the high-resolution
structure of LeuTAa as a template, strongly suggest that
C74 is in the first transmembrane domain near the mem-
brane–extracellular fluid interface and is partially buried in
the membrane (Yamashita et al. 2005; Beuming et al. 2006;
Livesay et al. 2007). As a practical matter, the relatively
short half-life of MTSET in physiological buffers
(*10 min) also necessitates the use of experimental con-
ditions that can achieve faster labeling of GAT1.
As GAT1-mediated GABA transport is Na?- and Cl--
coupled, we investigated the degree of MTSET labeling
when Na? or Cl- was isosmotically replaced with various
cations/anions in the labeling buffer. It is well established
that Na? and/or Cl- binding events to GAT1 cause trans-
porter conformational changes (Mager et al. 1993, 1996;
Golovanevsky and Kanner 1999; Lu and Hilgemann
1999b; Li et al. 2000; Bicho and Grewer 2005; Karakossian
et al. 2005; Meinild et al. 2009). We reasoned that con-
formational changes induced by Na? and/or Cl- binding
may alter the accessibility of C74 to the extracellular space
and that, therefore, it was plausible to examine the degree
of labeling in buffers that lacked either one or both of these
cosubstrates. For most ion replacement conditions tested,
only a modest enhancement was observed in the ability of
MTSET to label GAT1, as judged by the reduction in the
GABA-evoked current (see Fig. 2). Two notable excep-
tions were replacement of Na? with Li? and replacement
of Cl- with valproate.
Consistent with previous reports on GAT1 and the
serotonin transporter (SERT), we observed a substantial
reduction in transport activity following MTSET labeling
when Li? replaced Na? in the labeling buffer (Figs. 2, 4)
(Ni et al. 2001; Meinild et al. 2009). In SERT, the
increased accessibility of C109 (homologous with GAT1
C74) is due to Li? binding rather than the absence of Na?
(Ni et al. 2001), and this is consistent with our findings in
GAT1 (Fig. 2). In GAT1, Li? by itself is not capable of
driving Li?/Cl-/GABA cotransport as the Li?-bound
transporter conformation is distinct from the Na?-bound
conformation (Meinild et al. 2009). However, in the pres-
ence of low concentrations of Na?, Li? can substitute for
Na? at one of the cation-binding sites, allowing for Li?/
Na?/Cl-/GABA cotransport (MacAulay et al. 2002;
Meinild and Forster 2012). Thus, in the presence of Li?
(Na? absent) GAT1 assumes a distinct conformation with
increased accessibility of C74 to the extracellular fluid.
Remarkably, the most significant environmental condi-
tion which favored GAT1 labeling by MTSET was when
Cl- was replaced with valproate (Figs. 2, 4). Valproate
increases the turnover rate of the GATs via an allosteric
mechanism that involves increasing the rate of Na? bind-
ing to the transporter, the transition that is thought to be the
rate-limiting step in the transport cycle (Whitlow et al.
2003; Soragna et al. 2005). Our data show that in the
presence of valproate complete MTSET labeling of GAT1
can be accomplished within 10 min (Fig. 4c) and suggest
that any future attempts to utilize C74 to label GAT1 in the
plasma membrane should use valproate as the major anion
in the labeling buffer.
Interestingly, the presence of GABA protected GAT1
from MTSET labeling (Fig. 2) (Zhou et al. 2004). This
suggests that during the normal translocation cycle (i.e.,
Na?/Cl-/GABA cotranslocation) there is a reduction in the
probability (i.e., time) that C74 is exposed to the extra-
cellular fluid and, hence, accessible to covalent modifica-
tion by MTSET.
We found it surprising that the accessibility of GAT1
C74 to the extracellular fluid and, hence, MTSET was not
altered by changes in experimental conditions such as
membrane potential, temperature or pH. GAT1 function is
highly voltage-dependent, and indeed, voltage-clamp
fluorometric measurements have provided strong evidence
for conformational changes evoked by voltage jumps (Li
et al. 2000; Meinild et al. 2009). Moreover, the rates of
both GAT1 steady-state and presteady-state kinetic prop-
erties are very temperature-dependent (Binda et al. 2002;
Gonzales et al. 2007). Finally, changes in the extracellular
pH have been reported to alter GAT1 function (Grossman
and Nelson 2002, 2003). Nonetheless, none of these con-
ditions appeared to play a significant role in the ability of
MTSET to label GAT1, suggesting that the global con-
formational changes caused by these factors do not lead to
a change in the accessibility of C74 to the extracellular
fluid. When labeling was performed at pH 5.0, there
appeared to be a decrease in the efficacy of MTSET;
however, this was very likely due to the significantly
decreased fraction of GAT1 C74 in the deprotonated thiol
form—the form that can nucleophilically attack and, thus,
react with MTSET. With a pKa of *8.37, only 0.04 % of
C74 thiol groups are predicted to be in the deprotonated
form at pH 5.0 (vs. 9.7 and 19.0 % at pH 7.4 and 9.0,
respectively). Indeed, there appeared to be a correlation
between the fraction of C74 in the deprotonated form and
loss of transporter function following MTSET treatment
(13, 47 and 56 % at pH 5.0, 7.4 and 9.0, respectively) (see
Fig. 3 for raw data).
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Having found improved experimental conditions for
sulfhydryl modification of GAT1 C74 with MTSET (i.e.,
labeling in the presence of valproate), we wished to
understand the mechanism by which MTSET labeling of
GAT1 C74 leads to a reduction in the GABA-evoked cur-
rent (IGABANaCl ). In principle, the reduction in I
GABA
NaCl may be
due to (1) a change in the transporter ion/GABA flux cou-
pling ratio (i.e., change in ion/substrate transport stoichi-
ometry); (2) a significant increase in the apparent affinity
constant (K0.5) values (i.e., reduction in the apparent affin-
ity) for the transporter cosubstrates Na?, Cl- and GABA;
(3) a reduction in transporter turnover rate (i.e., the rate at
which ion/GABA molecules are cotranslocated across the
plasma membrane per unit time); or (4) a complete loss of
GAT1 GABA transport activity when C74 is chemically
modified by MTSET. To study each of these possibilities,
we characterized the current that remained after partial
labeling of GAT1 with MTSET. Partial labeling was
achieved by incubating GAT1 with 1 mM MTSET for
5 min (at 21 C, Vm = -50 mV, pH 7.4) in order to
achieve *50 % reduction in IGABANaCl (see Figs. 1, 2, 3, 4).
The results of uptake under voltage-clamp experiments
suggest that the current that remains after MTSET sulf-
hydryl modification of GAT1 has the same ion/GABA flux
coupling ratio as that mediated by untreated GAT1: two net
positive charges for every GABA molecule translocated
across the plasma membrane (Fig. 5). GAT1 exhibits tight
coupling of charge flux and GABA flux under a variety of
experimental conditions, which suggests a fixed ion/sub-
strate transport stoichiometry (Gonzales et al. 2007; Mat-
thews et al. 2009). Therefore, if labeling with MTSET
alters the transport stoichiometry, the ratio of charge flux to
GABA flux should shift from the known value of 2. Our
results do not support this possibility. Thus, after MTSET
treatment, the GABA-evoked current is mediated by
transporters that operate with a normal Na?/Cl-/GABA
coupling stoichiometry.
After MTSET treatment, the remaining GABA-evoked
current had the same steady-state and presteady-state kinetic
parameters, as well as pharmacological properties, as those
of untreated GAT1 (Figs. 6, 7, 8). Thus, a reduction in the
apparent affinity of the cosubstrates cannot account for the
observed reduction in IGABANaCl after MTSET treatment.
After MTSET treatment, the GATs that contribute to the
observed macroscopic signal have the same turnover rate as
that of untreated GAT1 (Fig. 9). While the exact turnover
rate of the GATs and, in fact, most electrogenic Na?-coupled
transporters has been elusive due to technical limitations
(Gonzales et al. 2007), we have at our disposal a simple
measurement that provides an index of the transporter turn-
over rate. The ratio of the maximum steady-state GABA-
evoked current (Imax) to the maximum presteady-state
charge moved in response to voltage pulses (QNaCl or Qmax)
correlates with the transporter turnover rate (Loo et al. 1993;
Mager et al. 1993; Eskandari et al. 1997; Sacher et al. 2002;
Whitlow et al. 2003; Karakossian et al. 2005; Gonzales et al.
2007). These two parameters are independently measured in
individual GAT1-expressing cells, and each is directly
related to the total number of functional transporters in the
plasma membrane (Zampighi et al. 1995; Eskandari et al.
1997, 1998; Gonzales et al. 2007). Our results demonstrated
that, while both Imax and Qmax are reduced after labeling (see
Figs. 1 and 8), the ratio of Imax to Qmax was not altered fol-
lowing MTSET labeling (Fig. 9), suggesting that both
parameters were reduced proportionally and that the trans-
porter population that gives rise to these measurements
operates with the same turnover rate.
All in all, our data suggest that the observed current fol-
lowing partial labeling with MTSET is mediated by an
unlabeled transporter population that operates normally.
Transmembrane domain 1 is thought to play a prominent role
in GAT1 function by lining the permeation pathway and
containing determinants for substrate specificity (Mager
et al. 1996; Zhou et al. 2004; Yamashita et al. 2005). It is
highly unlikely that the bulky, positively charged MTSET,
covalently bonded to C74 at the extracellular end of trans-
membrane domain 1, does not alter the transport stoichi-
ometry or any of the relevant steady-state, presteady-state or
inhibition kinetic parameters of GAT1. It is more likely that
the observed GABA-evoked current following MTSET
exposure is mediated by transporters that were simply never
labeled. We conclude that MTSET labels GAT1 at C74 and
that such covalent sulfhydryl modification renders that
transporter completely nonfunctional and electrically silent.
At this time, it is difficult to reconcile our data with those
reported previously using the voltage-clamp fluorometry
method (Li et al. 2000; Meinild et al. 2009). The totality of
our data suggests that labeling C74 with MTSET renders the
transporter nonfunctional as all known electrical signals of
GAT1 are abolished after labeling. These signals include the
GABA-evoked steady-state current as well as voltage-
evoked presteady-state charge movements. Thus, at first
glance, it appears that a fluorophore-conjugated C74 is not a
suitable experimental model by which to examine trans-
porter conformational changes that are relevant to those
operating during the normal transport cycle. However, pre-
vious measurements obtained with the voltage-clamp fluo-
rometry method suggest that GAT1 conjugated (reportedly
at C74) with TMR6M exhibits voltage-induced changes in
fluorescence intensity and that the time course of these
transitions corresponds well to the relaxation time constants
of the presteady-state charge movements. Our data show that
TMR6M is capable of labeling both WT GAT1 and the
mutant GAT1 C74A (see Fig. 1d), suggesting that, in
854 J. J. Omoto et al.: Sulfhydryl Modification of GAT1 at Cysteine 74
123
addition to C74, this agent labels other cysteine residues,
possibly those buried in the membrane or even exposed to the
cytoplasmic space. Clearly, additional studies are needed to
better understand the electrophysiological and fluorescence
signals following GAT1 labeling with TMR6M. A challenge
with selecting suitable fluorescent probes is that their lipid
solubility coefficients are generally not known or cannot be
estimated (for proprietary molecules). We propose that the
simple assay shown here on GAT1 C74A may be performed
in order to assess the ability of the fluorophore to cross the
plasma membrane and, hence, gain access to internally
exposed cysteine residues.
A sequence alignment for members of the neurotrans-
mitter/Na? symporter family (NSS) reveals that the cys-
teine at position 74 of GAT1 is conserved in most of the
mammalian members of the family. However, each family
member is predicted to have different numbers of extra-
cellularly oriented cysteine residues, making it difficult to
utilize a single residue for labeling purposes without
engineering cysteine mutants against a cysteine-less back-
ground. Moreover, very different observations have been
reported regarding the functional consequence of labeling
with the membrane-impermeant MTSET. For example,
WT dopamine and norepinephrine transporters appear to be
insensitive to functional modification by extracellularly
applied MTSET (Sucic and Bryan-Lluka 2005). The SERT
exhibits significant functional sensitivity to MTSET only
when Li? is the major extracellular cation, and this effect is
abolished in the C109A mutant, where SERT C109 is
homologous to GAT1 C74 (Chen et al. 1997; Ni et al.
2001; Sucic and Bryan-Lluka 2005). In the glycine trans-
porter (GlyT1b), MTSET leads to a reduction in both
steady-state and voltage-evoked presteady-state currents,
and this effect is eliminated in the corresponding cysteine-
to-alanine mutant (Roux et al. 2001). The basic observa-
tions presented here on sulfhydryl modification of GAT1
with MTSET are similar to those reported for the glycine
transporter GlyT1b (Roux et al. 2001).
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